Significant OS Benefit with Glofitamab plus GemOx in Transplant-Ineligible Patients with Relapsed or Refractory DLBCL By Ogkologos - December 6, 2024 648 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the STARGLO study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR How I Coped With My Own Cancer Diagnoses As an Oncologist October 13, 2022 Neoadjuvant Atezolizumab Plus Chemotherapy Is Safe and Has Promising Activity in... January 11, 2024 Bone Marrow Transplant Drug May Improve Immunotherapy for Metastatic Breast Cancer March 11, 2019 New on NCI Websites for October 2018 October 30, 2018 Load more HOT NEWS EMA’s Safety Committee Has Concluded That the Benefits of Ifosfamide Solutions... It’s a fair COP: Why our chief clinician went to a... Researchers Have Harnessed a Compound from a Common Plant Called Feverfew... 24-Year-Old Woman with Terminal Breast Cancer Dreams of Fairytale Wedding with...
